IRGD

IRGD denotes an iRGD (internalising RGD) tumour penetrating peptide family member used in cancer research for cell systems, spheroids, nanoparticles, imaging constructs and early human work under names such as CEND 1/LSTA1/certepetide.

IRGD is associated with specialist translational research as a tumour penetrating cyclic RGD derived peptide studied in cell systems, spheroids, nanoparticle and imaging construct development, animal cancer models and early human programmes under development names such as CEND 1/LSTA1/certepetide.

IRGD: Batch documents are not yet linked on this site. For this tumour penetrating cyclic RGD derived peptide expected evidence includes batch identifier and release date; identity by liquid chromatography mass spectrometry/intact mass and sequence or cyclisation confirmation; analytical HPLC/UPLC chromatogram with method and purity limits; peptide content, counterion and residual solvent/water details; and cell penetration or functional assay data as applicable. No batch documentation is shown as available until the record for that specific item is linked and reviewed.

IRGD: Storage depends on the documented supplied presentation; as a tumour penetrating cyclic RGD derived peptide verify dry/lyophilised versus solution form, counterion and concentration, solvent or buffer selection, pH sensitivity, container closure compatibility and cyclic conformation stability including oxidation or ring integrity. No storage instruction is shown as available until the stability record for that specific item is linked and reviewed.